Uploaded February 2018 | Updated November 2026, 3 hours ago
At Access! 2018, AAM CEO Chip Davis urged the executives of member companies to engage proactively with state and federal legislators to help them understand the value proposition of generics and biosimilars and how our business model differs from that of the brand-name manufacturers.
“We have 90 percent of the market share versus the brand-name industry,” Chip continued, “but in terms of mind share those ratios are flipped, and they leverage that mind share very effectively.” He described how Big Pharma deflects attention away from itself, pointing fingers at insurers, pharmacy benefit managers and hospitals.
At Access! 2018, AAM CEO Chip Davis urged the executives of member companies to engage proactively with state and federal legislators to help them understand the value proposition of generics and biosimilars and how our business model differs from that of the brand-name manufacturers.
“We have 90 percent of the market share versus the brand-name industry,” Chip continued, “but in terms of mind share those ratios are flipped, and they leverage that mind share very effectively.” He described how Big Pharma deflects attention away from itself, pointing fingers at insurers, pharmacy benefit managers and hospitals.







![Save the Date for Access 2019 - Heading to New Orleans! [widescreen]
Access! is heading to New Orleans! Each year, AAMs annual meeting gathers industry leaders together to explore the business, the science, the technology, and the politics surrounding our industry. Over 50 exhibitors, multiple networking events and over 800 attendees attend. Plan to join us at Access! 2019 and save the date now. View the latest information about Access! 2019 at https://www.accessiblemeds.org/events or follow at #Access2019. Save the Date for Access 2019 - Heading to New Orleans! [widescreen]](https://i.ytimg.com/vi/rwk59eGIG5w/mqdefault.jpg)


